RxDoctor Payments Data

Rajeshree Dimkpa, MD

Psychiatry · Salisbury, NCNPI 1194793240

Payments from drug & device makers

$6,933in general payments, 2019–2025

Across 421 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$835
  • Neurocrine Biosciences, Inc.$552
  • Almatica Pharma LLC$537
  • Otsuka America Pharmaceutical, Inc.$419
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,73097%
  • Education$2033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,933 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,336
Medicare patients
116
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate43$366,652
Invega SustennaPaliperidone Palmitate42$119,192
AustedoDeutetrabenazine18$95,794
VraylarCariprazine Hcl60$92,445
RexultiBrexpiprazole25$36,919
Risperdal ConstaRisperidone Microspheres24$36,668
Buprenorphine Hcl382$17,595
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl145$16,501
TrintellixVortioxetine Hydrobromide28$16,203
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$10,336
VyvanseLisdexamfetamine Dimesylate26$9,843
Paliperidone ErPaliperidone51$8,224
Chlorpromazine Hcl30$5,533
Oxcarbazepine122$5,250
Ziprasidone Hcl96$4,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$552$366,65243 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$149$155,86066 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,196$95,79418 claims
AbbVieVraylar$835$92,44560 claims
Otsuka America Pharmaceutical, Inc.Rexulti$419$36,91925 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$13$26,04554 claims
Indivior Inc.Suboxone$16$10,33620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →